Clinical significance of serum asprosin level in patients with early renal damage of essential hypertension

doi:10.11958/20231349

Abstract

Abstract:

Objective To investigate the clinical significance and serum changes of asprosin (ASP) levels in patients with essential hypertension and early renal damage. Methods According to urinary albumin / creatinine ratio (UACR), 160 patients with essential hypertension were divided into the simple hypertension group (78 cases) and the early renal damage group (82 cases). Another 60 healthy subjects were selected as the control group. The differences of serum ASP, interleukin-6 (IL-6) and UACR levels were compared between groups. The correlation between ASP and blood pressure, IL-6 and UACR was analyzed. Logistic regression analysis was used to analyze the factors influencing early renal damage in essential hypertension. Receiver operating characteristic (ROC) curve was used to analyze the predictive value of each index for early renal injury. Results The serum levels of ASP, IL-6 and UACR were higher in the early renal damage group than those in the control group and the simple hypertension group (all P<0.05). The serum levels of ASP and IL-6 showed an increasing trend with the increase of blood pressure. ASP was positively correlated with systolic blood pressure (SBP), diastolic blood pressure (DBP) and IL-6 levels in patients with essential hypertension (all P<0.05). Serum ASP was positively correlated with SBP, UACR and IL-6 levels in essential hypertension patients (P<0.05), and serum ASP was positively correlated with UACR and IL-6 levels in the early renal damage group (P<0.05). Logistic regression analysis showed that higher levels of SBP, ASP and IL-6 were independent risk factors for early renal damage. ROC curve showed that ASP had the largest area under the curve (AUC) of 0.972 (95%CI: 0.950-0.993). The AUC of combined detection of ASP+IL-6+SBP was 0.986 (95%CI:0.972-0.999). Conclusion The increased serum ASP level in patients with early renal damage in essential hypertension is a good predictor of early renal damage. The combined detection of ASP+IL-6+SBP is better than single detection.

Key words: essential hypertension, kidney diseases, interleukin-6, albuminuria, ROC curve, asprosin

CLC Number:

R544.11，R692

Figures/Tables 9

References 19

[1]	UNGER T, BORGHI C, CHARCHAR F, et al. 2020 international society of hypertension global hypertension practice guidelines[J]. Hypertension, 2020, 75(6):1334-1357. doi:10.1161/HYPERTENSIONAHA.120.15026.
[2]	DE MIGUEL C, PELEGRIN P, BAROJA-MAZO A, et al. Emerging role of the inflammasome and pyroptosis in hypertension[J]. Int J Mol Sci, 2021, 22(3):1064. doi:10.3390/ijms22031064.
[3]	LI B, HOU C, LI L X, et al. The associations of adipokines with hypertension in youth with cardiometabolic risk and the mediation role of insulin resistance:the BCAMS study[J]. Hypertens Res, 2023, 46(7):1673-1683. doi:10.1038/s41440-023-01243-9.
[4]	SHABIR K, GHARANEI S, ORTON S, et al. Asprosin exerts pro-inflammatory effects in THP-1 macrophages mediated via the Toll-like receptor 4(TLR4) pathway[J]. J Mol Sci, 2022, 24(1):227. doi:10.3390/ijms24010227.
[5]	DENG X, ZHAO L, GUO C, et al. Higher serum asprosin level is associated with urinary albumin excretion and renal function in type 2 diabetes[J]. Diabetes Metab Syndr Obes, 2020, 13(11):4341-4351. doi:10.2147/DMSO.S283413.
[6]	AMEER O Z. Hypertension in chronic kidney disease:what lies behind the scene[J]. Front Pharmacol, 2022, 13(10):949260. doi:10.3389/fphar.2022.949260.
[7]	ZHANG Z, ZHAO L, ZHOU X, et al. Role of inflammation,immunity,and oxidative stress in hypertension:new insights and potential therapeutic targets[J]. Front Immunol, 2023, 13(1):1098725. doi:10.3389/fimmu.2022.1098725.
[8]	CLEMENTE-SUAREZ V J, REDONDO-FLOREZ L, BELTRAN-VELASCO A I, et al. The role of adipokines in health and disease[J]. Biomedicines, 2023, 11(5):1290. doi:10.3390/biomedicines11051290.
[9]	OKAMURA Y, NIIJIMA R, KAMESHIMA S, et al. Human omentin-1 administration ameliorates hypertensive complications without affecting hypertension in spontaneously hypertensive rats[J]. Int J Mol Sci, 2023, 24(4):3835. doi:10.3390/ijms24043835.
[10]	ROMERE C, DUERRSCHMID C, BOURNAT J, et al. Asprosin,a fasting-induced glucogenic protein hormone[J]. Cell, 2016, 165(3):566-579. doi:10.1016/j.cell.2016.02.063.
[11]	OVALI M A, BOZGEYIK I. Asprosin,a C-terminal cleavage product of fibrillin1 encoded by the FBN1 gene,in health and disease[J]. Mol Syndromol, 2022, 13(3):175-183. doi:10.1159/000520333.
[12]	MAZUR-BIALY A I. Asprosin enhances cytokine production by a co-culture of fully differentiated mature adipocytes and macrophages leading to the exacerbation of the condition typical of obesity-related inflammation[J]. Int J Mol Sci, 2023, 4(6):5745. doi:10.3390/ijms24065745.
[13]	WANG X L, WANG J X, CHEN J L, et al. Asprosin in the paraventricular nucleus induces sympathetic activation and pressor responses via cAMP-dependent ROS production[J]. Int J Mol Sci, 2022, 23(20):12595. doi:10.3390/ijms232012595.
[14]	ARABI T, SHAFQAT A, SABBAH B N, et al. Obesity-related kidney disease:beyond hypertension and insulin-resistance[J]. Front Endocrinol(Lausanne), 2022, 13(1):1095211. doi:10.3389/fendo.2022.1095211.
[15]	XU L, CUI J, LI M, et al. Association between seruma asprosin and diabetic nephropathy in patients with type 2 diabetes mellitus in the community:a cross-sectional study[J]. Diabetes Metab Syndr Obes, 2022, 15(1):1877-1884. doi:10.2147/DMSO.S361808.
[16]	GOODARZI G, SETAYESH L, FADAEI R, et al. Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy[J]. Mol Biol Rep, 2021, 48(7):5443-5450. doi:10.1007/s11033-021-06551-2.
[17]	MAZUR-BIALY A I. Asprosin-a fasting-induced glucogenic,and orexigenic adipokine as a new promising player. Will it be a new factor in the treatment of obesity,diabetes,or infertility? A review of the literature[J]. Nutrients, 2021, 13(2):620. doi:10.3390/nu13020620.
[18]	HAO Y, LI X, ZHU Y, et al. Effect of age and isolated systolic or diastolic hypertension on target organ damage in non-dialysis patients with chronic kidney disease[J]. Aging(Albany NY), 2021, 13(4):6144-6155. doi:10.18632/aging.202609.
[19]	SAGI B, KESOI I, VAS T, et al. Relationship between arterial stiffness,left ventricular diastolic function,and renal function in chronic kidney disease[J]. BMC Nephrol, 2023, 24(1):261. doi:10.1186/s12882-023-03308-w.

组别	n	年龄/ 岁	性别（男/女）	吸烟	BMI/ （kg/m²）
对照组	60	53.52±11.64	35/25	17（28.33）	26.00±2.83
单纯高血压组	78	49.44±11.01	53/25	21（26.92）	26.38±3.23
早期肾损害组	82	51.66±10.86	54/28	22（26.83）	26.76±3.08
F、χ²或Z		2.231	1.468	0.132	1.064

组别	n	年龄/ 岁	性别（男/女）	吸烟	BMI/ （kg/m²）
对照组	60	53.52±11.64	35/25	17（28.33）	26.00±2.83
单纯高血压组	78	49.44±11.01	53/25	21（26.92）	26.38±3.23
早期肾损害组	82	51.66±10.86	54/28	22（26.83）	26.76±3.08
F、χ²或Z		2.231	1.468	0.132	1.064

组别	n		BUN/(mmol/L)		SCr/ (mmol/L)		TC/(mmol/L)	TG/ (mmol/L)
对照组	60		5.75±1.06		69.11±9.03		4.60±0.71	1.55（1.29，2.05）
单纯高血压组	78		5.97±1.58		71.23±7.56		4.84±0.90	1.67（1.30，2.24）
早期肾损害组	82		6.22±1.58		72.50±10.63		4.87±0.84	1.68（1.24，2.49）
F或Z			1.766		1.754		2.271	0.003
组别		LDL-C/ (mmol/L)		FBG/ (mmol/L)		SBP/ mmHg			DBP/ mmHg
对照组		2.42±0.66		5.25±0.42		118.55±9.55			68.80±7.16
单纯高血压组		2.72±0.78		5.28±0.44		143.23±11.74^a			91.35±11.28^a
早期肾损害组		2.65±0.80		5.23±0.34		149.82±13.40^ab			101.39±10.05^ab
F		2.910		0.202		128.229^＊＊			193.832^＊＊

组别	n		BUN/(mmol/L)		SCr/ (mmol/L)		TC/(mmol/L)	TG/ (mmol/L)
对照组	60		5.75±1.06		69.11±9.03		4.60±0.71	1.55（1.29，2.05）
单纯高血压组	78		5.97±1.58		71.23±7.56		4.84±0.90	1.67（1.30，2.24）
早期肾损害组	82		6.22±1.58		72.50±10.63		4.87±0.84	1.68（1.24，2.49）
F或Z			1.766		1.754		2.271	0.003
组别		LDL-C/ (mmol/L)		FBG/ (mmol/L)		SBP/ mmHg			DBP/ mmHg
对照组		2.42±0.66		5.25±0.42		118.55±9.55			68.80±7.16
单纯高血压组		2.72±0.78		5.28±0.44		143.23±11.74^a			91.35±11.28^a
早期肾损害组		2.65±0.80		5.23±0.34		149.82±13.40^ab			101.39±10.05^ab
F		2.910		0.202		128.229^＊＊			193.832^＊＊

组别		n	高血压分级（1/2/3级）	高血压病程/年		降压药物应用时间/年
单纯高血压组		78	20/26/32	5.46±2.61		4.00（2.00，6.00）
早期肾损害组		82	21/28/33	7.01±2.88^a		5.00（3.00，7.25）
t、χ²或Z			0.014	3.565^＊＊		1.998^＊
组别	β受体阻滞剂		CCB	ACEI/ARB	ARNI	利尿剂
单纯高血压组	21（26.92）		43（55.13）	45（57.69）	11（14.10）	5（6.41）
早期肾损害组	20（24.39）		45（54.88）	47（57.32）	11（13.41）	6（7.31）
χ²	0.135		0.045	0.446	1.240	1.019